Pick a time period -
No more available filters You need to apply a filter before selecting newsroom

Use our filters to get your customized news. Save and subscribe to as many filters as you want, get the news that YOU are interested in right in your mailbox, RSS feed or in your personalized dashboard. Share your stories, news, multimedia and pressreleases and get a wider audience with news.cision.com.

Interim Report January–September 2019

Strong financial positionKey highlights · Underlying sales and profitability growth excluding the KM7 impact · Strong balance sheet after sale of a majority stake in Bergvik Skog Öst · Increased focus on efficiency and profitability Quarterly data · Net sales declined by 4% to SEK 5 833 million (6 054), driven mainly by volume and mix impact of KM7 start-up. · Adjusted EBITDA* was SEK 639 million (893), negatively impacted by KM7 start-up effects of around SEK 280 million. · Operating profit was SEK 149 million (513). · Net profit was SEK 5 754 million (363),

Pandox AB (publ) interim report January–September 2019

A balanced earnings development July-September 2019 · Revenue from Property Management amounted to MSEK 851 (810). For comparable units the increase was 2.6 percent, adjusted for currency effects · Net operating income from Property Management amounted to MSEK 761 (698), MSEK 748 excl. the effects of IFRS 16. For comparable units the increase was 1.7 percent, adjusted for currency effects · Net operating income from Operator Activities amounted to MSEK 160 (142), MSEK 153 excl. the effects of IFRS 16. For comparable units the decrease was 1.2 percent, adjusted for currency

ICA Gruppen interim report Q3 2019

Stable earnings development – ICA Bank in partnership on new mortgage company· Consolidated net sales amounted to SEK 29,818 million (28,846), an increase of 3.4% · Operating profit excluding items affecting comparability was SEK 1,599 million (1,499). Recalculated for IFRS 16, operating profit for the comparison period in 2018 was SEK 1,549 million · Profit for the period was SEK 1,202 million (1,082) · Profit includes capital losses on sales of non-current assets and impairment losses totalling SEK -4 million net (-96) · Earnings per share were SEK 5.96 (5.36) · Cash flow

Orkla ASA: Improvement for Orkla

Orkla’s operating profit (EBIT adj.) increased by 7% in the third quarter to a total of NOK 1,444 million. Operating revenues also rose by 7%, to NOK 10,880 million. President and CEO Ivar Semlitsch has initiated a project to strengthen Orkla’s competitiveness. The Branded Consumer Goods business achieved organic turnover growth of 1.5% and a 6.2% improvement in operating profit. “Orkla’s Branded Consumer Goods business has had a satisfactory quarter, with both top-line and bottom-line growth. All four business areas delivered organic growth in the quarter. It is positive to see that

Q3 Financial Report 2019

Nordea Bank Abp – Inside information – Interim report (Q1 and Q3) CEO Frank Vang-Jensen’s comments on the results: “In the third quarter, both net interest and net commission income increased from higher business volumes. Net fair value decreased following significant interest rate movements during the summer. Total revenues are down 2% in local currencies. Our Q3 operating loss of EUR 421m includes several one-off items totalling EUR 1.3bn, comprising of an impairment charge for IT intangibles of EUR 735m, a restructuring provision of EUR 204m, an expense related to sale of Luminor

One-off items with significant negative impact to the Q3 results and new outlook announced

Nordea Bank Abp – Inside information Impairment of capitalised IT systems, restructuring provision and loan loss provision The Board of Directors has today, in connection with the approval of the third quarter 2019 interim report, approved several one-off items having a significant negative impact on the Group’s Q3 results. The Q3 operating loss of EUR 421m includes one-off items amounting to EUR 1.3bn, comprising of an impairment charge for IT intangibles of EUR 735m, a restructuring provision of EUR 204m, an additional loan loss provision of EUR 282m and an expense related to the

Bauhaus: The party never stops!

Fall in BauhausLand: Natural beauty outdoors; fascinating exhibitions indoorsThroughout this anniversary year, exhibitions celebrating the Bauhaus have been, still are, and will continue to be stimulating. And with the spectacular fall foliage, this is the ideal time to tour BauhausLand. The Great Outdoors really is glorious with ancient beech forests and rare wildlife, including the European wildcat. Natural beauty and Bauhaus design: A perfect partnership!    The Bauhaus was born in Weimar, and an hour west is the Hainich National Park. The Canopy Walk, stretching all of 1,750 feet,

Lundin Mining Announces Declaration of Dividend

Toronto, October 23, 2019 /CNW? (TSX: LUN; Nasdaq Stockholm: LUMI) Lundin Mining Corporation (“Lundin Mining” or the “Company”) today announced that its Board of Directors has declared a dividend of CAD$0.03 per share, payable on December 18, 2019, to shareholders of record at the close of business on December 6, 2019. This dividend qualifies as an 'eligible dividend' for Canadian income tax purposes. The declaration, timing, amount and payment of future dividends remain at the discretion of the Board of Directors. Dividends on shares traded on the Toronto Stock Exchange (“TSX”) will be

Lundin Mining Third Quarter Results

Toronto, October 23, 2019 /CNW/ (TSX: LUN; Nasdaq Stockholm: LUMI) Lundin Mining Corporation (“Lundin Mining” or the “Company”) today reported cash flows of $111.6 million generated from operations in the third quarter. Net earnings attributable to Lundin Mining shareholders were $26.4 million ($0.04 per share) for the quarter ended September 30, 2019. Third quarter net earnings include a negative revaluation on derivative liabilities related to the acquisition of the Chapada mine of $16.0 million ($0.02 per share), a negative variable consideration adjustment related to metal streaming

Lucara Third Quarter 2019 Results to be Release Monday, November 4, 2019

Vancouver, British Columbia, October 23, 2019 /CNW/ (LUC – TSX, LUC – BSE, LUC – Nasdaq Stockholm) Lucara Diamond Corp. (“Lucara” or the “Company”) announces that it will be publishing its 2019 Third Quarter Results on Monday, November 4, 2019, after market close in North America. The Company will host a conference call and webcast to discuss the results on Tuesday, November 5, 2019 at 6:00 a.m. Pacific, 9:00 a.m. Eastern, 2:00 p.m. UK, 3:00 p.m. CET. CONFERENCE CALL:Please call in 10 minutes before the conference call starts and stay on the line (an operator will be available to

Double Bond Pharmaceutical receives Eurasian patent for the BeloGal® platform

Double Bond Pharmaceuticals patent application for organ-specific administration of hydrophilic cancer drug to the liver which forms the basis for the BeloGal® technology platform has been granted by the Eurasian Patent Organization (EAPO). Patent approval provides protection for the technology platform BeloGal® and products on the territory of 8 member states at least through 2035. "It is the company's second granted patent and we are very pleased that it concerns the geographically largest market. With the patent, we have achieved an important interim goal for the commercialization of

Mycronic launches a new mask writer for the semiconductor industry

Mycronic AB (publ) launches SLX, a new laser-based mask writer for the semiconductor industry. The introduction of the SLX also marks the company’s re-entry into this market, with the first shipment expected around year end 2020. The SLX is launched to meet a rising demand for low-end photomasks for the semiconductor industry driven by long term trends as well as to support an upcoming replacement and modernization cycle. Estimates indicate a total market need of 5-8 new writers per year in the coming years, with the market for laser-based mask writers estimated at USD 30-50 million.

SSC and DLR to strengthen Europe’s capacity for rocket development

Swedish Space Corporation (SSC) and German Aerospace Center (DLR) have signed an MOU for the development of test facilities for micro launcher engine and stage tests. The agreement will include exchanging facilities, knowledge and staff, providing Europe with the infrastructure for the entire range of rocket tests, including early stage “higher risk” tests, as well as increasing the capacity to provide for more companies to test their products. Through this collaboration, the testing capabilities at Lampoldshausen in Germany and Esrange Space Center in Sweden can be optimized. ”There

Major League Baseball Players Alumni Association Brings Legends for Youth Baseball Clinic Series to Solana Beach, CA

Free youth baseball clinic to feature seven MLB AlumniColorado Springs, Colo. – Local youth will have an opportunity to play with their big league heroes at the Major League Baseball Players Alumni Association (MLBPAA) Legends for Youth baseball clinic series on Saturday, October 26th, 2019. Sponsored by Chick-Fil-A Encinitas Horiz  and in conjunction with Santa Fe Christian High School, the free clinic features former Major League Baseball players who will teach baseball skills, drills and life lessons, concluding with an

MUNTERS EUROPEAN DATA CENTERS OPERATION INCURS ADDITONAL COSTS

Munters European Data Centers operations will make a provision for additional non-recurring costs of estimated SEKm 116 in the third quarter 2019 related to the closure of the Data Center factory in Dison, Belgium. The estimated costs are incurred due to certain specified components, for a previously sold customized Munters solution, having to be replaced at a specific customer’s sites.As announced previously and as part of the Munters Full Potential Program, Munters is in the process of closing its European Data Centers factory. In relation to the closure process, specified components, for

Intrum and Piraeus Bank close transaction and create leading credit management services platform in Greece

Following customary regulatory approvals, Intrum and Piraeus Bank have closed the transaction, first announced in June, that creates a leading management services platform in Greece. The transaction is a long-term strategic partnership, with Piraeus Bank owning 20 per cent of the shares in the new company.Under the terms of the transaction, Intrum has acquired Piraeus Bank's platform for servicing non-performing loans and consolidated it into a newly established company, which will be named Intrum Hellas. Intrum owns 80 per cent of the shares in Intrum Hellas, with Piraeus Bank owning the

United Bankers Corporation: Acquisition of Own Shares 23.10.2019

United Bankers Corporation NOTIFICATION 23.10.2019 at 18:30 UNITED BANKERS CORPORATION: ACQUISITION OF OWN SHARES 23.10.2019 Date 23.10.2019Exchange transaction BuyShare class UNIAVAmount 680Average price/share 8.8750 EURHighest price/share 8.9000 EURLowest price/share 8.8500 EURTotal price 6,035.00 EUR The shares held by United Bankers Corporation on 23.10.2019: UNIAV 30,039 On behalf of United Bankers CorporationSkandinaviska Enskilda Banken AB (Publ) Antti Salakka

Asarina Pharma intends to carry out a directed share issue

Asarina Pharma AB (publ) (Nasdaq First North Growth Market: ASAP) (”Asarina Pharma” or the “Company”) today announces its intention to execute a directed share issue to institutional investors (the “Issue”).The subscription price and the total number of new shares in the Issue will be determined through a bookbuild process (the “Bookbuilding”). The intention is that the number of new shares will not exceed 2,159,148. The Bookbuilding will start immediately following this announcement. Pricing and allocation of the new shares is expected to take place before beginning of trading on Nasdaq

HCL Technologies reports quarterly results for the FY quarter ending on September 30, 2020

REVENUE 2,486 million USD – up 18.4% YoT REVENUE GROWTH (CONSTANT CURRENCY) up 20.5% YoY EARNINGS BEFORE INTEREST & TAX (EBIT) 496 million  - up 18.8% YoY NET INCOME 376 million – up 5.5% YoY Key Highlights − HCL’s strong growth at 20.5% YoY in constant currency, led by double digit growth across Segments. IT and Business Services 17.4%, Products & Platforms 57.9%, Engineering and R&D Services 15.0% (on YoY Constant Currency basis). − HCL Software, a new business unit of HCL Products & Platforms, became operational in Q2, enhancing the revenue contribution from Financial

#19-1099 Delisting of certain derivatives from NGM

Certain derivatives will be delisted from NGM.For more details see attached files. For further information concerning this NGM notice please contact: Listing department on +46 8 566 390 20 or at listings@ngm.se Nordic Growth Market NGM AB About NGMNordic Growth Market NGM AB (NGM) is an authorized stock exchange with operations in Sweden, Norway, Denmark and Finland. The exchange is a wholly-owned subsidiary of Boerse Stuttgart, the leading retail exchange in Germany. NGM offers a complete marketplace for exchange traded products and provides a complete platform for companies

#19-1098 Listing of Derivatives at NGM

Information about various derivatives that will be listed at NGM.For more details see attached file. For further information concerning this NGM notice please contact: Listing on +46 8 566 390 20 or at listings@ngm.se. Nordic Growth Market NGM AB About NGMNordic Growth Market NGM AB (NGM) is an authorized stock exchange with operations in Sweden, Norway, Denmark and Finland. The exchange is a wholly-owned subsidiary of Boerse Stuttgart, the leading retail exchange in Germany. NGM offers a complete marketplace for exchange traded products and provides a complete platform for

Biotec Pharmacon ASA appoints Dr. Jethro Holter as interim CEO

(Tromsø/Oslo 23. October 2019) Biotec Pharmacon ASA (OSE: “BIOTEC”) announced today that its Board of Directors has unanimously appointed Dr Jethro Holter as the Company’s interim Chief Executive Officer. Jethro, who currently serves as the Managing Director of ArcticZymes AS, a subsidiary of Biotec Pharmacon, will succeed Christian Jorgensen, the current CEO, effective immediately.Jethro joined ArcticZymes as Managing Director in January 2015. He focused on driving a  new strategic direction focusing the subsidiary’s efforts towards growth, through expanding its B2B client base and

Gabather AB presents preclinical and clinical data of the Lead Drug Candidate, GT-002, at the American Society for Neurosciences (AfN) meeting in Chicago.

Gabather AB announces that today the company has a poster presentation summarizing the preclinical and clinical data of GT-002 at the AfN meeting in Chicago. The meeting is the biggest scientific meeting within Neurosciences with more than 26 500 international participants. The presentation includes the preclinical data accumulated during the last years as well as clinical data from the previous phase Ia study in healthy volunteers that was finalized in the second quarter of 2019 (Single Ascending Dose study, SAD). ”We are both proud and happy to present our data and research at this

There are no items matching the current filter
There are no more items matching the current filter
Back to top